New shot could tame rare fat disorder and stop pancreas attacks

NCT ID NCT05089084

Ongoing Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Feb 04, 2026 · Last updated May 01, 2026 · Updated 7 times

Summary

This study tests a new medicine called plozasiran in 75 adults with familial chylomicronemia syndrome (FCS), a rare genetic condition causing extremely high blood fats. The goal is to see if the drug safely lowers triglycerides and reduces the risk of pancreatitis. Participants receive four shots of either the drug or a placebo, then all can get the drug for two more years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Site 1

Boca Raton, Florida, 33434, United States
Clinical Site 10

Córdoba, X5003DCE, Argentina
Clinical Site 11

Formosa, 3600, Argentina
Clinical Site 12

Melbourne, 3081, Australia
Clinical Site 13

Nedlands, 6009, Australia
Clinical Site 14

Camperdown, New South Wales, 2050, Australia
Clinical Site 15

St Leonards, New South Wales, 2065, Australia
Clinical Site 16

Melbourne, Victoria, 3004, Australia
Clinical Site 17

Graz, 8036, Austria
Clinical Site 18

Edegem, 2650, Belgium
Clinical Site 19

Ghent, 9000, Belgium
Clinical Site 2

Suwanee, Georgia, 30024, United States
Clinical Site 20

Leuven, 3000, Belgium
Clinical Site 21

Liège, 4000, Belgium
Clinical Site 22

London, Ontario, N6A 5B7, Canada
Clinical Site 23

Toronto, Ontario, M5G 2C4, Canada
Clinical Site 24

Chicoutimi, Quebec, G7H 7K9, Canada
Clinical Site 25

Montreal, Quebec, H2W 1R7, Canada
Clinical Site 26

Québec, Quebec, G1V 4W2, Canada
Clinical Site 27

Zagreb, 10000, Croatia
Clinical Site 28

Paris, 75013, France
Clinical Site 29

Marseille, Cedez 05, 13385, France
Clinical Site 3

Indianapolis, Indiana, 46290, United States
Clinical Site 30

Jena, 7740, Germany
Clinical Site 31

Leipzig, 4103, Germany
Clinical Site 32

Galway, H91 YR71, Ireland
Clinical Site 33

Jerusalem, 9112001, Israel
Clinical Site 34

Chiba, 260-8677, Japan
Clinical Site 35

Ishikawa, 920-8641, Japan
Clinical Site 36

Osaka, 598-0048, Japan
Clinical Site 37

Tochigi, 329-0498, Japan
Clinical Site 38

Tokyo, 113-8655, Japan
Clinical Site 39

Tokyo, Japan
Clinical Site 4

Elkridge, Maryland, 21075, United States
Clinical Site 40

Mexico City, 11650, Mexico
Clinical Site 41

Tlalpan, Mexico DF, 14000, Mexico
Clinical Site 42

Cuernavaca, Morelos, 62250, Mexico
Clinical Site 43

Auckland, 2025, New Zealand
Clinical Site 44

Auckland, 1010, New Zealand
Clinical Site 45

Christchurch, 8011, New Zealand
Clinical Site 46

Muscat, Oman
Clinical Site 47

Lodz, 93-338, Poland
Clinical Site 48

Belgrade, 11000, Serbia
Clinical Site 49

Niš, 18000, Serbia
Clinical Site 5

St Louis, Missouri, 63110, United States
Clinical Site 50

Singapore, 119074, Singapore
Clinical Site 51

Gwangju, 61469, South Korea
Clinical Site 52

Seoul, 03080, South Korea
Clinical Site 53

A Coruña, 15001, Spain
Clinical Site 54

Granada, 18012, Spain
Clinical Site 55

Madrid, 28007, Spain
Clinical Site 56

Santiago de Compostela, 15706, Spain
Clinical Site 57

Izmir, 35100, Turkey (Türkiye)
Clinical Site 58

Melikgazi, Kayseri, 38030, Turkey (Türkiye)
Clinical Site 6

New York, New York, 10029, United States
Clinical Site 7

New York, New York, 10016, United States
Clinical Site 8

Austin, Texas, 78731, United States
Clinical Site 9

Norfolk, Virginia, 23510, United States

Conditions

Explore the condition pages connected to this study.

FAMILIAL CHYLOMICRONEMIA